Six policy solutions to help patients afford their insulin
By Holly Campbell | April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
OIG proposed rule could help strengthen the Part D market
By Holly Campbell | March 28, 2019
Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...
Read More
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
By Holly Campbell | March 25, 2019
Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...
Read More
OptumRX: Sharing rebates with patients is “worth it”
By Holly Campbell | March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...
Read More
Guest post: Copay accumulator adjustment programs lead to four times higher treatment discontinuation for patients with high deductibles
By Guest Contributor | February 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
By Holly Campbell | February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...
Read More
New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions
By Holly Campbell | January 18, 2019
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not...
Read More
10 things you should know about medicine spending and costs
By Holly Campbell | January 2, 2019
Updated on 03/07/2019 Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that...
Read More
Six key facts about the market for insulins
By Holly Campbell | December 17, 2018
The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts...
Read More
Medicare Monday (100)
340B Spotlight (40)
Cost & Consequence (0)
